NANOG and hepatocellular carcinoma: The results showed that there was no significant difference in the binding of H3K56la to SOX2 and Nanog promoter regions in HCC cells versus LCSCs, nor was there any significant change in the binding of H3K56la to SOX2 and Nanog promoter regions in LCSCs after treatment with lactate, siLDHA, and glycolysis inhibitors (Figure S4f, Supporting Information).